The present invention relates to a class of monoclonal antibody that specifically binds to phosphorylated serine residue 396 in hyperphosphorylated pathological tau (PHF) (pS396) with improved affinity, as well as methods of using these molecules and its tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.